Screening for HSV-2 infection in STD clinics and beyond: A few answers but more questions

Sexually Transmitted Diseases

Volumn 36, Issue 11, 2009, Pages 729-731

  Douglas Jr , John M ^a   Berman, Stuart M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR;

EDITORIAL; GENITAL HERPES; HEALTH PROGRAM; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION PREVENTION; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRESCRIPTION; PREVALENCE; PRIMARY PREVENTION; PUBLIC HEALTH SERVICE; SECONDARY PREVENTION; SEROLOGY; VIRUS TRANSMISSION;

ANTIBODIES, VIRAL; HEALTH PLAN IMPLEMENTATION; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MASS SCREENING;

EID: 70350774326     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181c04dea     Document Type: Editorial

References (34)

1. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973.
2. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008; 3:e2230.
3. Wald A, Krantz E, Selke S, et al. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis 2006; 194:42-52.
4. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med 2009; 169:1233-1240.
5. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
6. Corey L. Raising the consciousness for identifying and controlling viral STDs: Fears and frustrations-Thomas Parran Award Lecture. Sex Transm Dis 1998; 25:58-69.
7. Handsfield HH, Stone KM, Wasserheit JN. Prevention agenda for genital herpes. Sex Transm Dis 1999; 26:228-231.
8. Corey L, Handsfield HH. Genital herpes and public health: Addressing a global problem. JAMA 2000; 283:791-794.
9. Hook EW, Leone P. Time to translate new knowledge into practice: A call for a national genital herpes control program. J Infect Dis 2006; 194:6-7.
10. Rietmeijer CA, Low N. Herpes complex. Sex Transm Infect 2008; 84:330-331.
11. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: Implications for prevention of transmission. J Infect Dis 2008; 198:1098-1100.
12. Ashley RL, Wald A. Genital herpes: Review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev 1999; 12:1-8.
13. Centers for Disease Control and Prevention Sex Transm Dis Treatment Guidelines, 2006. MMWR Recomm Rep 2006; 55:1-94.
14. U.S. Preventive Services Task Force. Screening for Genital Herpes: Recommendation Statement. AHRQ Publication No. 05-0573-A. Rockville, MD: Agency for Healthcare Research and Quality, 2005. Available at http://www.ahrq.gov/ clinic/uspstf05/ herpes/herpesrs.htm.
15. Fortenberry JD, Zimet GD, Brady R, et al. Return for results after herpes simplex virus type 2 screening. Sex Transm Dis 2004; 31:655-658. (Pubitemid 39426396)
16. Zimet GD, Rosenthal SL, Fortenberry JD, et al. Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis 2004; 31:655-658.
17. Fife KH, Van Der Pol B, Roth AM. Sex Transm Dis Implementation of routine access to herpes simplex virus 2 antibody testing in a public health STD clinic. Sex Transm Dis. In press.
18. Sperling RS, Fife KH, Warren TJ, et al. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes. Sex Transm Dis 2008; 35:286-290.
19. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2007. Atlanta, GA: U.S. Department of Health and Human Services, 2008.
20. Whittington WL, Celum CL, Cent A, et al. Use of a glycoprotein G-based type-specific assay to detect antibodies to herpes simplex virus type 2 among persons attending sexually transmitted disease clinics. Sex Transm Dis 2001; 28:99-104.
21. Golden MR, Ashley-Morrow R, Swenson P, et al. Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis 2005; 32:771-777.
22. Mark HD, Nanda JP, Roberts J, et al. Performance of focus ELISA tests for HSV-1 and HSV-2 antibodies among university students with no history of genital herpes. Sex Transm Dis 2007; 34:681-685.
23. Turner KR, Wong EH, Kent CK, et al. Serologic herpes testing in the real world: Validation of new type-specific serologic herpes simplex virus tests in a public health laboratory. Sex Transm Dis 2002; 29:422-425.
24. Morrow RA, Friedrich D, Meier A, et al. Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. BMC Infect Dis 2005; 5:84.
25. Ashley-Morrow R, Nollkamper J, Robinson NJ, et al. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004; 10:530-536.
26. Eing BR, Lippelt L, Lorentzen EU, et al. Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2. J Clin Microbiol 2002; 40:407-413.
27. Crosby RA, Head S, DiClemente RJ, et al. Do protective behaviors follow the experience of testing positive for herpes simplex type 2? Sex Transm Dis 2008; 35:787-790.
28. Williams JR, Jordan JC, Davis EA, et al. Suppressive valacyclo-vir therapy: Impact on the population spread of HSV-2 infection. Sex Transm Dis 2007; 34:123-131.
29. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
30. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
31. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
32. Celum C, Wald A, Lingappa J, et al. Twice-daily acyclovir to reduce HIV-1 transmission from HIV-1 / HSV-2 co-infected persons within HIV-1 serodiscordant couples: A randomized, double-blind, placebo-controlled trial [abstract no.WELBC101]. Paper presented at: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 2009; Cape Town, South Africa.
33. White RG, Freeman EE, Orroth KK, et al. Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex Transm Infect 2008; 84(suppl 2):ii12-ii18.
34. Vermund SH, Allen KL, Karim QA. HIV-prevention science at a crossroads: Advances in reducing sexual risk. Curr Opin HIV AIDS 2009; 4:266-273.